Dyslipidemia and DM are groups of metabolic disorders which constitute major health problems
worldwide. EVOO has been used in a folk medicine to treat diabetes, which have a potent effect
in decreasing glucose level, triglyceride, cholesterol, LDL, and increased HDL, which studied
previously.
EVOO lowered glucose level in diabetic patient and healthy people (Covas, 2007). Several
studies revealed the importance of EVOO to manage the blood glucose level in diabetes type 2
patients, which may be due to the effect of its phenolic bioactive compounds such as: oleuropein,
hydroxytyrosol, tyrosol, tocopherol…etc, these compounds have antioxidant activity, and give
protection against metabolic diseases associated with oxidative stress such as diabetes. EVOO
has not found in other plant oils, hasantioxidative properties of these compounds, olive oil might
diminish the production of advanced glycosylated end products such as HbA1c
Phenolic compounds that are present in olive oil are commonly associated with increased levels
of HDL-cholesterol and in improvements in endothelial function. Additionally, polyphenolic compounds, including the phenolic acids, flavonoids, resveratrol and proanthocyanidins, might
affect glucose metabolism via an inhibition of carbohydrate absorption and digestion, a reduction
of glucose release from the liver or a stimulation of glucose uptake in peripheral tissues effect of
EVOO improved blood levels of LDL
EVOO increased HDL in patient and healthypeople with higher total phenols . HDL levels have
been inversely related to risk of coronary heart disease. The blood level of HDL is primarily
determined by genetics
Daily use of at least 10ml/75kg of EVOO can improve the lipid profile with decreases in LDL
and increasing in HDL, the use of EVOO will improve fasting and postprandial lipids by
decreasing lipid oxidation and providing phenols (especially oleuropein) that work as general
antioxidants. The health benefits of EVOO are strongly related to phenol content, with the
monounsaturated fat content providing a much less significant role.
Keywords: Dyslipidemia; metabolic disorders; EVOO, LDL, HDL
https://ijbpas.com/pdf/2019/August/MS_IJBPAS_2019_4706.pdf
Download PDF
https://doi.org/10.31032/IJBPAS/2019/8.8.4706
